Artiva Biotherapeutics, Inc. Finance Lease, Right-of-Use Asset, after Accumulated Amortization
Artiva Biotherapeutics, Inc. (ARTV) had Finance Lease, Right-of-Use Asset, after Accumulated Amortization of $180.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:FinanceLeaseRightOfUseAsset · last filed 2026-08-06
- 2026-06-30: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $180.00K.
- 2026-03-31: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $196.00K.
- 2025-12-31: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $212.00K.
- 2025-09-30: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $216.00K.
| Period end | Finance Lease, Right-of-Use Asset, after Accumulated Amortization |
|---|---|
| 2026-06-30 | $180.00K 10-Q · filed 2026-08-06 |
| 2026-03-31 | $196.00K 10-Q · filed 2026-05-08 |
| 2025-12-31 | $212.00K 10-Q · filed 2026-08-06 |
| 2025-09-30 | $216.00K 10-Q · filed 2025-11-12 |
| 2025-06-30 | $231.00K 10-Q · filed 2025-08-06 |
| 2025-03-31 | $246.00K 10-Q · filed 2025-05-08 |
| 2024-12-31 | $261.00K 10-K · filed 2026-03-10 |
| 2024-09-30 | $276.00K 10-Q · filed 2024-11-12 |
| 2024-06-30 | $291.00K 10-Q · filed 2024-08-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |